1. Catalog
  2. From Case to Conference: Creating a High Impact Ca ...
From Case to Conference: Creating a High Impact Case Study Poster
Create Account
Availability
Registration Required
Online Meeting
Aug 11, 2026 12:00 PM - 1:00 PM ET
Cost
$0.00
Credit Offered
No Credit Offered
  • Description
  • Learning Objectives
  • Faculty and Disclosures
  • Privacy Policy
New for 2026, the Scientific Program Committee (SPC) is accepting case report submissions from trainees and advanced practice providers (APPs). Join an expert panel discussion covering the key steps to developing a successful submission—from identifying a compelling case and crafting a scientifically sound abstract to designing an effective poster and addressing ethical considerations.

Designed to promote multidisciplinary scholarly engagement in liver disease, this session is especially valuable for APPs, fellows, and trainees, but is open to all interested in submitting a case report for The Liver Meeting 2026.
Upon completion of this activity, a participant should be able to:

• Describe the essential components of a high-quality case report submission, including case selection, abstract development, poster design, and ethical considerations.
• Apply a step-by-step approach to transform a clinical case into a scholarly case report suitable for submission and presentation at The Liver Meeting 2026.
This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Dawn Drazek, MSN, NP, A-GPCNP-BC, AF-AASLD:
Scientific Consultant/Advisor: Gilead, Ipsen, Madrigal, Intercept, Mirum, GlaxoSmithKline

Janet Gripshover, NP, AF-AASLD, CRNP:
 Scientific Consultant: 89Bio, Madrigal, Mirum
Speaker's Bureau: AbbVie, Intercept, Gilead, Salix

Summer Collier, DNP, APRN, FNP-BC (invited):
Nothing to Disclose

Vinay Jahagirdar, MBBS
Nothing to Disclose
Powered By